Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CID-078 |
| Synonyms | |
| Therapy Description |
CID-078 binds to Cyclin A and B and prevents the interaction of E2F1 with Cyclin A-Cdk2 and MYT1 with Cyclin B-Cdk1, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (J of Thorac Oncol 19, no. 10 (2024): S455). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CID-078 | CID 078|CID078 | CID-078 binds to Cyclin A and B and prevents the interaction of E2F1 with Cyclin A-Cdk2 and MYT1 with Cyclin B-Cdk1, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (J of Thorac Oncol 19, no. 10 (2024): S455). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06577987 | Phase I | CID-078 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |